(Information sent by the signatory company)
-Discovery Life Sciences launches a world-class proteomic services division with the support of leading technology partners
Create a single source for large-scale population studies, biobank characterization, and multi-omics biomarker analysis to support drug and diagnostic development.
HUNTSVILLE, Ala., Dec. 14, 2022/PRNewswire/ -- Discovery Life Sciences™ (Discovery) today announced the launch of its new Proteomic Services Division and is now accepting samples from pharmaceutical and biotech companies, governments and research centers academic and non-profit. This innovative offering includes exploratory and targeted proteomics using the Seer Proteograph™ suite of products, SCIEX LC-MS/MS systems, Olink® Proximity Extension Assay (PEA) and Luminex xMAP® platforms.
Discovery's Proteomic Services Labs are now integrated with its market-leading short and long read genomic services labs and its extensive global commercial biorepository of hyper-annotated® biospecimens.
"We are excited to open our doors to researchers and scientists from around the world and provide them with access to Discovery's large-scale multi-omics services to advance their large-scale research, clinical development and biomarker discovery programs," said Michael Pisano. , Executive Vice President of Discovery Proteomics. "Our proteomics experts carefully designed, built, and optimized a comprehensive, platform-agnostic suite of cutting-edge proteomics and proteo-genomics technologies to support all biomarker strategies, large-scale population studies, and biobank characterization projects."
As part of its strategy to expand biomarker services, Discovery signed a multi-year agreement in January with Seer, Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, and SCIEX , a world leader in life science analytical technologies, to form a first-of-its-kind Proteogenomics Consortium (PGC) for large-scale plasma proteomic studies. The PGC combines the proprietary technologies and expertise of the three companies to offer unbiased, high-resolution proteogenomics services that help discover new biomarkers that can be associated with underlying genetic variations.
"The Proteogenomics Consortium strategically unites these highly advanced plasma proteomics technologies with our world-leading expertise in short and long read genomics to more easily add deep and unbiased proteomic data to discovery, translational, and clinical studies, as well as programs." of large-scale population research," said Glenn Bilawsky, CEO of Discovery. "In addition, the PGC also enables the creation of new diagnostic tools for cancer, neurodegenerative, inflammatory, infectious diseases, and other therapeutic areas."
Then in September, Discovery announced that it was the largest certified merchant service provider for the Olink® PEA platform in the Americas. Olink PEA is a unique immuno-PCR technology that solves the dynamic range problem that has hampered plasma proteomics for decades, enabling the detection and quantification of low-abundance proteins in plasma at scale. Discovery will also implement complementary multiplex immunoassay platforms, including Luminex's xMAP® technology, which enables customizable protein- and nucleic acid-based multiplex assays.
Discovery offers a wide range of services, including genomics, proteomics, pathology, and cell biology. In addition to its broad portfolio of services, Discovery has the world's largest commercial biorepository, offering its partners a unique chain of custody to accelerate clinical research and development. Discovery's integrated, multi-omics workflow enables clients to gain deeper insights while preserving their valuable samples.
About Discovery Life Sciences
Discovery Life Sciences is the specialist biospecimen, biomarker and proteogenomics company, combining the world's largest commercial biospecimen inventory and acquisition network with preeminent laboratories for multiomics biomarker services, including genomics, tissue biomarker, proteomics and cellular services for accelerate new therapies supported by biomarker programs and companion diagnostics for cancer, infectious diseases, and other rare and complex conditions.
Through AllCells®, our cell and gene therapy division, we maintain the largest pool of recoverable donors to supply clinical-grade, research-only (RUO) fresh and cryopreserved human cell materials to support cell and gene therapy programs in any stage of development and at any scale.
Driven by leading scientific expertise and innovative use of today's technologies, the Discovery team is committed to helping clients quickly overcome obstacles and deliver results to make critical research and development decisions at market-leading speed. We are science at your service™! For more information, visit dls.com.
About Olink
Olink Holding AB (publ) (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community across multiple disease areas to enable new discoveries and improve the lives of patients. Olink offers a platform of products and services that are deployed at major pharmaceutical companies and leading clinical and academic institutions to deepen understanding of human biology in real time and drive 21st century healthcare through actionable and impactful science. . The company was founded in 2016 and is well established in Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.
About SCIEX
SCIEX offers solutions for the precise detection and quantification of molecules, enabling our customers to protect and enhance the well-being and safety of all. We have been at the forefront of mass spectrometry for 50 years. Since the launch of the first commercially successful triple quadrupole in 1981, we have developed revolutionary technologies and solutions that influence research and results that change lives.
Today, we continue to pioneer robust mass spectrometry and capillary electrophoresis solutions. Our customers are able to respond quickly to environmental hazards, better understand disease-relevant biomarkers, improve patient care in the clinic, bring relevant medicines to market faster, and keep food healthier and safer.
That's why thousands of life science experts around the world choose SCIEX for the answers they can trust to better inform critical decisions that positively impact life.
For more information, visit www.sciex.com.
About Seer
Seer™ is a life sciences company developing transformative products that open a new door to the proteome. Seer's Proteograph™ suite of products is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform rapid, deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by almost any laboratory. Seer's Proteograph suite of products is for research use only and is not intended for diagnostic procedures. For more information, visit www.seer.bio.
Logo - https://mma.prnewswire.com/media/1022478/Discovery_LS_Logo.jpg
View original content: https://www.prnewswire.com/news-releases/discovery-life-sciences-lanza-una-division-de-servicios-proteomicos-de-categoria-mundial-301702955.html
